Lily Dara
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (9)
Year:
2026
Year:
2026
Year:
2025
Over the past decade, immune checkpoint inhibitors (ICIs) have transformed the treatment of cancer, though they come with the risk of immune‐related adverse (irAEs) events such as hepatotoxicity or Immune‐mediated Liver Injury from Checkpoint Inhibitors (ILICI). ILICI is a serious irAE that, when severe, requires cessation of ICI and initiation of immunosuppression. Cytotoxic T Lymphocytes (CTLs) play a central role in ILICI; however, they are just part of the picture as immunotherapy broadly impacts all aspects of the immune microenvironment and can directly and indirectly activate innate and adaptive immune cells. Clinically, as our understanding of this entity grows, we encounter new challenges. The presentation of ILICI is heterogeneous with respect to latency, pattern of injury (hepatitis vs. cholangitis) and severity. This review focuses on our knowledge regarding risk factors, presentation and treatment of ILICI including ILICI refractory to steroids. An emerging topic, the possibility of rechallenge while accepting some risk, in patients who experience ILICI but require immunotherapy, is also discussed. This review provides an update on the current knowns and unknowns in ILICI and highlights several knowledge gaps where studies are needed.
Year:
2025
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2020
Collaborators (3)
Constantine Karvellas
Professor
University of Alberta
Jennifer Dodge
Associate Professor
University of Southern California
Brian T. Lee
Loma Linda University Health
Make your next move.
Prepare your application
Review drafts before you send them.